Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir

Kevin P. Vo, Philip Vutien, Matthew J. Akiyama, Vinh D. Vu, Nghiem B. Ha, Joy I. Piotrowski, James Wantuck, Marina M. Roytman, Naoky Tsai, Ramsey Cheung, Jiayi Li, Mindie H. Nguyen

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

Background: There are limited data analyzing the effectiveness of boceprevir (BOC) or telaprevir (TVR) in combination with pegylated interferon (PEG-IFN) plus ribavirin (RBV) in a real-life patient cohort. Aims: In clinical trials, patients with chronic hepatitis C (CHC) treated with BOC or TVR plus PEG-IFN and RBV achieved sustained virological response (SVR) rates of 70 %. However, it is not clear whether similar results can be realized in routine practice. Our goal is to examine SVR rates of these triple regimens for CHC in a multicenter real-life patient cohort. Methods: We retrospectively studied 200 consecutive CHC genotype 1 patients who were initiated on PEG-IFN, RBV, and either TVR (n = 113) or BOC (n = 87) from July 2011 to February 2014 at two US academic liver clinics, a Veterans Affairs liver clinic and a community gastroenterology clinic. Results: Both BOC and TVR treatment groups were similar in regard to comorbidities, BMI, and HCV RNA levels. BOC patients were more likely to have cirrhosis than TVR patients (47 vs. 24 %, P = 0.001). SVR rates were low in both cohorts (40 % for BOC, 53 % for TVR, P = 0.05). On multivariate logistic regression, treatment adherence by the “80/80/80 rule,” diagnosis of cirrhosis, and use of erythropoietin were statistically significant predictors for SVR. Of these, treatment adherence was the strongest predictor (OR 4.43, 95 % CI 2.8–6.06, P < 0.001). Conclusion: SVR was much lower in a real-life patient cohort than in clinical trials (53 % for TVR and 40 % for BOC, compared to 66–75 % in clinical trials).

Original languageEnglish (US)
Pages (from-to)1045-1051
Number of pages7
JournalDigestive Diseases and Sciences
Volume60
Issue number4
DOIs
StatePublished - Apr 1 2015
Externally publishedYes

Keywords

  • BOC
  • Effectiveness
  • HCV
  • PEG-IFN
  • Routine practice
  • TVR

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir'. Together they form a unique fingerprint.

  • Cite this